Dive into the archives.
- Teva completes enrollment in second Phase III trial
Jun 26, 2009 (Datamonitor via COMTEX) — Teva Pharmaceutical Industries, an Israeli generic pharmaceutical company, and Active Biotech, a Swedish pharmaceutical company, have completed patient enrollment for the second pivotal Phase III clinical trial, Bravo, evaluating the novel, oral once-daily immunomodulating compound, laquinimod, for the treatment of relapsing-remitting multiple sclerosis.
// Bravo is a global clinical [...]
- Hot off the AAN Press: Cladribine Reduces Relapses, Disability, Disease Progression
April 29, 2009
Merck KGaA on Wednesday presented detailed results from a previously announced Phase III study of investigational oral multiple sclerosis drug cladribine at the American Academy of Neurology annual conference. The findings demonstrated that annual short-course treatment with cladribine significantly reduced the rate of clinical relapses, disability progression and brain lesions in patients [...]
- Novartis MS drug linked to new side effect
LONDON, April 14 — Fresh side-effect problems have emerged with Novartis AG’s experimental oral multiple sclerosis (MS) drug FTY720, with doctors reporting a case of haemorrhaging focal encephalitis.
A case report on the patient who developed the condition after taking part in a Phase III clinical trial of the medicine — one of the big hopes [...]
- Dirucotide (BioMS) Phase III U.S. Trial Gets Positive Safety Review From Data Safety Monitoring Board
Edmonton, Alberta, April 14, 2009 – BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company’s U.S. pivotal phase III MAESTRO-03 trial of dirucotide in patients with secondary progressive MS has completed a safety analysis and recommended [...]
- SPMS Treatment Update: Spotlight on dirucotide (BioMS Medical Corp.)
BioMS Medical Announces 2008 Year End Results
Edmonton, Alberta, March 17, 2009 – BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the year ended December 31, 2008.
“Dirucotide has demonstrated the ability to safely affect MS progression in previous studies and we look [...]
